← All indications
Oropharyngeal Neoplasms
Tumors or cancer of the OROPHARYNX.
Subtype terms (1)
More specific conditions that are subtypes of Oropharyngeal Neoplasms in the MeSH hierarchy.
- Tonsillar Neoplasms
2 drugs (1 approved, 1 experimental)
Drugs by status
Phase 4 trials (3)
Phase 3 trials (16)
Phase 2 trials (61)
- ino-3112
- fluorothymidine
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- methylprednisolone
- 68ga-nota-ae105
- alx148
- bmx-001
- bowman-birk inhibitor
- prednisone
- valproic acid
- e6 tcr
- e7 tcr transduced pbl cells
- entinostat
- ficlatuzumab
- gemcitabine
- aldesleukin
- hydroxyurea
- ipatasertib
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- nimotuzumab
- alpelisib
- ipilimumab
- interleukin-12
- sitagliptin
- sacituzumab govitecan
- celecoxib
- cyclophosphamide
- tremelimumab
- utomilumab
- veliparib
- +31 more
Phase 1 trials (22)
- 7-hydroxystaurosporine
- alvespimycin
- irinotecan
- photochlor
- hpv specific t cells
- motexafin gadolinium
- onyx-015
- lidocaine
- methylene blue
- everolimus
- allogeneic adipose derived mesenchymal stem cell
- Peposertib
- sargramostim
- inbrx-105
- HPV16-E7-T512
- elimusertib
- flubhpve6e7
- rp-3500
- zimberelimab
- nexi-003 t cells
- hryz-t101
- Autologous tumor vaccine
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (29)
- AstraZeneca
- National Cancer Institute (NCI)
- Velindre NHS Trust
- Huazhong University of Science and Technology
- Centre Jean Perrin
- Centre Leon Berard
- ECOG-ACRIN Cancer Research Group
- Henry Ford Health System
- NRG Oncology
- Radiation Therapy Oncology Group
- UNICANCER
- University of Birmingham
- Mayo Clinic
- Cardiff University
- Fudan University
- Groupe Oncologie Radiotherapie Tete et Cou
- University of Copenhagen
- Jiao Tong University
- François Rabelais University
- Institut Gustave Roussy
- University of Texas at Houston
- Free University of Brussels
- University of Nice Sophia Antipolis
- Washington University in St. Louis
- BOIRON
- Zila Biotechnology, Inc.
- People's Liberation Army of China
- University of Lorraine
- Monopar Therapeutics
Organization Involved with Phase 2 Indications (53)
- Celgene
- Bristol-Myers Squibb
- Merck
- Merck KGaA
- Pfizer
- Novartis
- Biotech Pharmaceutical Co., Ltd.
- ISA Pharmaceuticals
- Trial Form Support S.L.
- National Institutes of Health (NIH)
- University of Jena
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Canadian Cancer Trials Group
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Cornell University
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- Instituto do Cancer do Estado de São Paulo
- Johns Hopkins University
- McGill University
- New York University
- Ohio State University
- Southwest Oncology Group
- Stanford University
- University of Iowa
- +23 more
Organization Involved with Phase 1 Indications (20)
- Advaxis, Inc.
- Pharmacyclics
- Cleveland BioLabs
- Hookipa Biotech
- Agennix
- The EMMES Corporation
- AIDS Malignancy Consortium
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- University of London
- Harvard University
- Duke University
- Hoosier Cancer Research Network
- Sanford Health
- Sanford Research
- University of Liverpool
- Virginia Commonwealth University
- University of Colorado, Denver
- Vanderbilt University
- Recipharm
Organization Involved with Other Experimental Indications (6)